Posted by Michael Wonder on 05 Jul 2023
European Commission grants conditional marketing authorisation for Taiho's Lytgobi tablets for the treatment of adults with cholangiocarcinoma
4 July 2023 - Lytgobi is the first irreversibly binding FGFR inhibitor in the European Union for use in the treatment of patients with cholangiocarcinoma.
Taiho Oncology Europe and Taiho Pharmaceutical announced today that the European Commission has granted conditional marketing authorisation for Lytgobi (futibatinib) monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
